Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study of Hemospan® for Treating Hypotension in Hip Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled to undergo elective primary hip arthroplasty (based on an osteoarthritis diagnosis) under spinal anesthesia~* Adult male or female (surgically sterile or post-menopausal), aged 50 years or older~* American Society of Anesthesiology (ASA) Class II or III~* Physical examination, laboratory status, vital signs, and ECG within acceptable limits for the planned surgery, as judged by the investigator~* Have been given written and verbal information by the investigator about Hemospan and the protocol, and have had the opportunity to ask questions about the study~* Patients must sign an Informed Consent form that has been reviewed and approved by the independent Ethics Committee~Exclusion Criteria:~* Hip fracture patients and nail/pin extraction procedures~* Clinical evidence of uncontrolled cardiovascular, infectious, psychiatric, metabolic or systemic disorders including diabetes and rheumatoid arthritis~* Evidence of significant hypertension with SBP \>180 mmHg, or a difference in SBP obtained in each arm that is \>15 mmHg (measured in the supine position in both arms, at screening)~* Recent history or evidence of MI or stroke (within 6 months)~* Known alcohol or drug dependency~* Currently taking oral anti-coagulant therapy; except for low-dose aspirin (acetylsalicylic acid), \<200 mg/day~* History of coagulopathy~* Involved in any investigational drug or device trial within 30 days prior to this study~* Professional or ancillary personnel involved with this study

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hemospan (MP4OX) (Type: EXPERIMENTAL): 4.3 g/dL MalPEG-Hb solution
- Control (Type: ACTIVE_COMPARATOR): Voluven (HES 130/0.4)

Based on this trial design, predict the completion outcome and termination type (if applicable).